La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Sino Biopharmaceutical Gestione

Gestione criteri di controllo 1/4

Sino Biopharmaceutical's Il CEO è Eric S. Y. Tse, nominato in Jul2022, e ha un mandato di 2.08 anni. la retribuzione annua totale è CN¥ 49.69M, composta da 45.4% di stipendio e 54.6% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 22.27% delle azioni della società, per un valore di HK$ 13.18B. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 1.6 anni e 9.3 anni.

Informazioni chiave

Eric S. Y. Tse

Amministratore delegato

CN¥49.7m

Compenso totale

Percentuale dello stipendio del CEO	45.4%
Mandato del CEO	2.1yrs
Proprietà del CEO	22.3%
Durata media del management	1.6yrs
Durata media del Consiglio di amministrazione	9.3yrs

Aggiornamenti recenti sulla gestione

Recent updates

Are Investors Undervaluing Sino Biopharmaceutical Limited (HKG:1177) By 48%?

Jul 12

Here's Why Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt Responsibly

May 21

Sino Biopharmaceutical Limited's (HKG:1177) 27% Cheaper Price Remains In Tune With Earnings

Apr 21

What Does The Future Hold For Sino Biopharmaceutical Limited (HKG:1177)? These Analysts Have Been Cutting Their Estimates

Apr 03

Sino Biopharmaceutical Limited's (HKG:1177) Intrinsic Value Is Potentially 34% Above Its Share Price

Mar 20

Sino Biopharmaceutical Limited's (HKG:1177) Shares May Have Run Too Fast Too Soon

Dec 18

Does Sino Biopharmaceutical (HKG:1177) Have A Healthy Balance Sheet?

Dec 02

Sino Biopharmaceutical Limited (HKG:1177) Shares Could Be 41% Below Their Intrinsic Value Estimate

Nov 17

We Think Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt With Ease

Aug 30

Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 50% Undervaluation?

May 26

Sino Biopharmaceutical (HKG:1177) Has A Rock Solid Balance Sheet

Apr 20

Is Sino Biopharmaceutical Limited (HKG:1177) Trading At A 38% Discount?

Feb 09

Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 41% Undervaluation?

Nov 11

Sino Biopharmaceutical (HKG:1177) Seems To Use Debt Quite Sensibly

Oct 24

Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 46% Undervaluation?

Jul 08

Is Sino Biopharmaceutical (HKG:1177) Using Too Much Debt?

Apr 28

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Eric S. Y. Tse rispetto agli utili di Sino Biopharmaceutical?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jun 30 2024	n/a	n/a	CN¥2b
Mar 31 2024	n/a	n/a	CN¥2b
Dec 31 2023	CN¥50m	CN¥23m	CN¥2b
Jun 30 2023	n/a	n/a	CN¥2b
Mar 31 2023	n/a	n/a	CN¥2b
Dec 31 2022	n/a	n/a	CN¥2b
Sep 30 2022	n/a	n/a	CN¥5b
Jun 30 2022	n/a	n/a	CN¥8b
Mar 31 2022	n/a	n/a	CN¥14b
Dec 31 2021	CN¥23m	CN¥6m	CN¥15b
Sep 30 2021	n/a	n/a	CN¥12b
Jun 30 2021	n/a	n/a	CN¥10b
Mar 31 2021	n/a	n/a	CN¥4b
Dec 31 2020	CN¥25m	CN¥7m	CN¥3b
Sep 30 2020	n/a	n/a	CN¥2b
Jun 30 2020	n/a	n/a	CN¥3b
Mar 31 2020	n/a	n/a	CN¥3b
Dec 31 2019	CN¥6m	CN¥870k	CN¥3b

Compensazione vs Mercato: La retribuzione totale di Eric S. Y. ($USD 6.97M ) è superiore alla media delle aziende di dimensioni simili nel mercato Hong Kong ($USD 913.61K ).

Compensazione vs guadagni: La retribuzione di Eric S. Y. è aumentata di oltre il 20% nell'ultimo anno.

AMMINISTRATORE DELEGATO

Eric S. Y. Tse (28 yo)

2.1yrs

Mandato

CN¥49,691,000

Compensazione

Mr. Eric S. Y. Tse serves as an Executive Director at Sino Biopharmaceutical Limited since October 23, 2019 and serves as its Chief Executive Officer since July 28, 2022. Mr. Tse joined Sino Biopharmaceuti...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Y. Y. Tse	Executive Chairwoman of the Board	9.2yrs	CN¥49.69m	0.033% CN¥ 19.4m
Eric S. Y. Tse	CEO & Executive Director	2.1yrs	CN¥49.69m	22.27% CN¥ 13.1b
Ping Tse	Founder & Senior Executive Vice Chairman	4yrs	CN¥49.53m	9.19% CN¥ 5.4b
Cheung Ling Cheng	Executive Vice Chairwoman of the Board	7.3yrs	CN¥43.13m	16.31% CN¥ 9.6b
Zhoushan Tian	Executive Director	no data	CN¥1.91m	Nessun dato
Hsin Tse	Senior VP & Executive Director	no data	CN¥6.41m	1.96% CN¥ 1.2b
Chun Ling Li	Chief Financial Officer	1.6yrs	Nessun dato	Nessun dato
Song Jin	Vice President of Public Affairs	no data	Nessun dato	Nessun dato
Sean Chen	Chief Strategy Officer	1.6yrs	Nessun dato	Nessun dato
Orphanides George	Chief Scientific Advisor of invoX	1.6yrs	Nessun dato	Nessun dato
Chau Ling Yu	Assistant VP & Financial Controller	no data	Nessun dato	Nessun dato
Oi Nin Chan	Company Secretary	9yrs	Nessun dato	Nessun dato

1.6yrs

Durata media

54yo

Età media

Gestione esperta: Il team dirigenziale di 1177 non è considerato esperto (durata media 1.6 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Y. Y. Tse	Executive Chairwoman of the Board	9.2yrs	CN¥49.69m	0.033% CN¥ 19.4m
Eric S. Y. Tse	CEO & Executive Director	4.8yrs	CN¥49.69m	22.27% CN¥ 13.1b
Ping Tse	Founder & Senior Executive Vice Chairman	4yrs	CN¥49.53m	9.19% CN¥ 5.4b
Cheung Ling Cheng	Executive Vice Chairwoman of the Board	7.3yrs	CN¥43.13m	16.31% CN¥ 9.6b
Zhoushan Tian	Executive Director	9.3yrs	CN¥1.91m	Nessun dato
Hsin Tse	Senior VP & Executive Director	no data	CN¥6.41m	1.96% CN¥ 1.2b
Zhengfei Lu	Independent Non-Executive Director	18.8yrs	CN¥376.00k	Nessun dato
Dakui Li	Independent Non-Executive Director	19.9yrs	CN¥376.00k	Nessun dato
Lu Fu Zhang	Independent Non-Executive Director	9.3yrs	CN¥376.00k	Nessun dato
Hong Lu	Independent Non-Executive Director	9.3yrs	CN¥342.00k	Nessun dato
Kwok Tung Li	Independent Non-Executive Director	3.7yrs	CN¥376.00k	0.00039% CN¥ 229.3k

9.3yrs

Durata media

60yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 1177 sono considerati esperti (durata media dell'incarico 9.3 anni).

Sino Biopharmaceutical Gestione

Gestione criteri di controllo 1/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Sino Biopharmaceutical Limited Announces Retirement of Ms. Li Mingqin as Executive Director

Executive Chairwoman of the Board recently bought HK$5.8m worth of stock

Sino Biopharmaceutical Limited, Annual General Meeting, Jun 05, 2024

Key Executive recently bought HK$34m worth of stock

Executive Vice Chairwoman of the Board recently bought HK$21m worth of stock

Less than half of directors are independent

Recent updates

Consensus EPS estimates increase by 11%

First half 2024 earnings released: EPS: CN¥0.16 (vs CN¥0.068 in 1H 2023)

Sino Biopharmaceutical Limited Announces Acceptance of New Indication Application for Marketing of Benmelstobart Injection in Combination with Anlotinib Hydrochloride Capsule for First-Line Treatment of Advanced Renal Cell Carinoma

Sino Biopharmaceutical Limited to Report Q2, 2024 Results on Aug 13, 2024

Sino Biopharmaceutical Limited Announces Interim Analysis of Phase III Clinical Trial of the Categroy 1 Innovative Drug Culmerciclib Capsule

Sino Biopharmaceutical Limited Announces Positive Results on Phase III Study of Anlotinib Hydrochloride Capsule in Combination with Chemotherapy for First-Line Treatment of Advanced Soft Tissue Sarcoma

Sino Biopharmaceutical Limited Announces Acceptance of New Drug Application for Categroy 1 Innovative Drug Rovadicitinib Tablet

Are Investors Undervaluing Sino Biopharmaceutical Limited (HKG:1177) By 48%?

Sino Biopharmaceutical Limited Receives Approval for Marketing of Liraglutide Injection

Sino Biopharmaceutical Limited Announces Approval for Marketing of Category 1 Innovative Drug Envonalkib Citrate Capsules "Envonalkib (TQ-B3139)"

Sino Biopharmaceutical Limited Announces Approval for Marketing of Gadoteridol Injection

Sino Biopharmaceutical Limited Announces Retirement of Ms. Li Mingqin as Executive Director

Upcoming dividend of HK$0.03 per share

Sino Biopharmaceutical Limited Announces Positive Results on Phase III Study of Benmelstobart Injection in Combination with Anlotinib Hydrochloride Capsules for First-Line Treatment of Advanced Renal Cell Carcinoma

Here's Why Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt Responsibly

Sino Biopharmaceutical Limited Receives Marketing Approval from National Medical Products Administration of China

Full year 2023 earnings: EPS and revenues miss analyst expectations

Sino Biopharmaceutical Limited Announces Approval for Marketing of Category 1 Unecritinib Fumarate Capsules

Investor sentiment improves as stock rises 18%

Executive Chairwoman of the Board recently bought HK$5.8m worth of stock

Sino Biopharmaceutical Limited's (HKG:1177) 27% Cheaper Price Remains In Tune With Earnings

Consensus revenue estimates fall by 13%

What Does The Future Hold For Sino Biopharmaceutical Limited (HKG:1177)? These Analysts Have Been Cutting Their Estimates

Sino Biopharmaceutical Limited, Annual General Meeting, Jun 05, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Sino Biopharmaceutical Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on 5 July 2024

Sino Biopharmaceutical Limited's (HKG:1177) Intrinsic Value Is Potentially 34% Above Its Share Price

Sino Biopharmaceutical Limited Provides Update on Development Progress of Mash Products "Lanifibranor" and "TQA2225"

Sino Biopharmaceutical Limited Announces Latest Results of Phase II Clinical Study of KRAS G12C Inhibitor Garsorasib Tablet

Sino Biopharmaceutical Limited to Report Fiscal Year 2023 Results on Mar 28, 2024

Sino Biopharmaceutical Limited Announces Acceptance of the New Indication Application for Marketing of Anlotinib Hydrochloride Capsules and Anti Pd-L1 Benmelstobart

Qingdao Ocean Innovative Products Investment Fund Co., Ltd. and Qingdao Ocean New Kinetic Energy Products Investment Fund (Limited Partnership) agreed to acquire 67% stake in CP Pharmaceutical (Qingdao) Co., Ltd from Sino Biopharmaceutical Limited (SEHK:1177) for CNY 1.8 billion.

Sino Biopharmaceutical Limited Announces Prioritised Evaluation Granted for KRAS G12c Inhibitor Garsorasib Tablet (D-1553)

Now 21% undervalued

Sino Biopharmaceutical Limited Announces Approval of Clinical Trial for Neuropathic Pain

Sino Biopharmaceutical Limited Announces Completion of Patient Enrollment in Phase III Clinical Trial of Anlotinib Combined with Chemotherapy in First-Line Treatment of Advanced Soft Tissue Sarcoma

Sino Biopharmaceutical Limited's (HKG:1177) Shares May Have Run Too Fast Too Soon

Sino Biopharmaceutical Limited Announces Phase I Clinical Research Results of Tqh2722

Sino Biopharmaceutical Limited Announces First Dose of the First Batch of Subjects in Phase I Clinical Trial of TQA3038

Does Sino Biopharmaceutical (HKG:1177) Have A Healthy Balance Sheet?

Sino Biopharmaceutical Limited (HKG:1177) Shares Could Be 41% Below Their Intrinsic Value Estimate

An unknown buyer acquired Suzhou Tianqing Xingwei Med./Lianyungang Chia Tai Tianqing Med./Zhejia Tianqing Zhongwei Med. from Sino Biopharmaceutical Limited (SEHK:1177) for approximately CNY 150 million.

Investor sentiment improves as stock rises 16%

Sino Biopharmaceutical Limited Announces Application for Phase Ib/II Clinical Trial of Innovative Drug

An unknown buyer acquired 84.2% stake in Shanghai Chia Tai Tongyong Pharmaceutical Co., Ltd. from Sino Biopharmaceutical Limited (SEHK:1177) for CNY 290 million.

Upcoming dividend of HK$0.02 per share at 2.7% yield

Sino Biopharmaceutical Limited Announces IND Application of Innovative Medicine TRD205 (AT2R Antibody) Filed with and Accept by FDA

We Think Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt With Ease

First half 2023 earnings released: EPS: CN¥0.068 (vs CN¥0.10 in 1H 2022)

Sino Biopharmaceutical Limited Announces Interim Cash Dividend for the Period Ended 30 June 2023, Payable on 27 October 2023

Sino Biopharmaceutical Limited to Report First Half, 2023 Results on Aug 25, 2023

Key Executive recently bought HK$34m worth of stock

Sino Biopharmaceutical Limited Announces Application for Marketing of Loxoprofen Sodium Cataplasms

Upcoming dividend of HK$0.06 per share at 3.0% yield

Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 50% Undervaluation?

Sino Biopharmaceutical Limited Announces New Drug Marketing Application for the Category 1 Innovative Anti-Tumor Medicine

Sino Biopharmaceutical Limited Announces Approval for Marketing by National Medical Products Administration of China for F-627 (Efbemalenograstim alfa Injection)

Sino Biopharmaceutical (HKG:1177) Has A Rock Solid Balance Sheet

Executive Vice Chairwoman of the Board recently bought HK$21m worth of stock

Full year 2022 earnings: EPS and revenues miss analyst expectations

Sino Biopharmaceutical Limited Announces Clinical Trial Application of Innovative Medicine "Tqb2103 (Claudin18.2 ADC)" Accepted by Center for Drug Evaluation

Is Sino Biopharmaceutical Limited (HKG:1177) Trading At A 38% Discount?

Sino Biopharmaceutical Limited Announces Application for Marketing of Category I Innovative Drug Tqb2450 Injection in Combination with Anlotinib Hydrochloride Capsules for the Indication of First-Line Treatment of Small Cell Lung Cancer

Sino Biopharmaceutical Limited Announces the Enrollment of All Patients in Phase III Clinical Trial of "Tqg203"

Less than half of directors are independent

Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 41% Undervaluation?

Sino Biopharmaceutical Limited Provides Revenue Guidance for 2023

Sino Biopharmaceutical (HKG:1177) Seems To Use Debt Quite Sensibly

Investor sentiment improved over the past week